

New Products - Bretaris Genuair

Bretaris Genuair (**aclidinium bromide**) is a competitive muscarinic receptor antagonist (anticholinergic), with subnanomolar affinity for all five human muscarinic receptor subtypes (M₁-M₅) and a longer residence time at the M₃ receptors than the M₂ receptors. Nonclinical in vitro and in vivo studies showed rapid, dose dependent and long-lasting inhibition by aclidinium bromide of acetylcholine induced bronchoconstriction. Aclidinium bromide is quickly broken down in plasma, the level of systemic anticholinergic side effects is therefore low. Bretaris Genuair is indicated as a long-term maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Bretaris Genuair is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, including ipratropium, oxitropium or tiotropium. It is also contraindicated in patients with rare hereditary problems of galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption (lactose content). Bretaris Genuair is available as an inhaler (aclidinium 322 microgram/dose) containing 30 doses and 60 doses.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.